Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

PIB: Development of Ayush entrepreneurship

Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate

This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.

SKYCovione will strengthen South Korea position in global COVID-19 vaccine industry, says GlobalData

This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines

Syngene reports revenue from operations up 8% in Q1 FY 23

Company raises the annual revenue guidance from mid-teens to high teens

Brii Bio inks partnership with China Resources Pharmaceutical to advance the commercialization of Long-acting COVID-19 neutralizing antibody therapy

The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China

Orchid Pharma updates on PLI scheme benefits for its subsidiary

The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"

Syngene signs 10-year biologics manufacturing agreement with Zoetis

Syngene's collaboration with Zoetis started in 2011